Baxter International said it has entered into an agreement to supply Britain with flu vaccine in the event of a bird flu pandemic.
The Deerfield, Ill., company is in the final stages of testing for a vaccine against H5N1 strains of avian influenza.
Baxter said it will manufacture its pandemic vaccine in a serum-free, vero cell-based system that accelerates vaccine availability. The company said vaccines produced using this process can be released within approximately 12 weeks, significantly earlier than with traditional egg-based systems.
The vero cell culture gives the company the flexibility to quickly respond to emerging variant pandemic virus strains, Baxter said in a news release.
The Chicago Tribune said the advanced supply agreement could be worth tens of millions of dollars to the company over the next four years.
British health officials said they signed more than $300 million in contracts with Baxter and GlaxoSmithKline to supply a vaccine as soon as the strain is identified by the World Health Organization.
Copyright 2007 by United Press International
Related stories:
Human trials of universal flu vaccine begin
Clinical trials of a new vaccine that could protect against multiple types of flu are beginning at Oxford University. If successful, the ‘universal’ flu injection would transform the way we vaccinate against influenza and could offer immunity to a bird flu pandemic.
Scientists examine bird flu infections to monitor for 'pandemic' mutations
Scientists funded by the Wellcome Trust are to examine what is preventing the H5N1 avian influenza virus from causing a human pandemic and what mutations are required to realise its deadly potential. The research could hold the key to early identification of a potential influenza pandemic, and to developing drugs and a vaccine.
New vaccine to fight multiple vaccine strains
A universal vaccine effective against several strains of influenza has passed its first phase of testing, according to Dr. Christine Turley of the University of Texas at Galveston.
1918 flu antibodies resurrected from elderly survivors
Ninety years after the sweeping destruction of the 1918 flu pandemic, researchers at Monroe Carell Jr. Children's Hospital at Vanderbilt have recovered antibodies to the virus – from elderly survivors of the original outbreak.
Personalized immunotherapy to fight HIV/AIDS
For a long time, the main obstacle to creating an AIDS vaccine has been the high genetic variability of the HIV virus. Dr. Jean-Pierre Routy and his team from the Research Institute of the McGill University Health Centre (MUHC), in collaboration with Dr. Rafick Sékaly from the Université de Montréal, have overcome this difficulty by designing a personalized immunotherapy for HIV-infected patients. The team's findings were presented on August 5 at the XVII International AIDS Conference in Mexico City.
Booster vaccination may help with possible future avian influenza pandemic
New evidence suggests that a booster vaccination against H5N1 avian influenza given years after initial vaccination with a different strain may prove useful in controlling a potential future pandemic. The study is published in the August 1 issue of The
Journal of Infectious Diseases, now available online.
Researchers identify potential new drug candidates to combat 'bird flu'
As the specter of a worldwide outbreak of avian or "bird flu" lingers, health officials recognize that new drugs are desperately needed since some strains of the virus already have developed resistance to the current roster of anti-flu remedies.
Penn animal study identifies new DNA weapon against avian flu
Researchers at the University of Pennsylvania School of Medicine have identified a potential new way to vaccinate against avian flu. By delivering vaccine via DNA constructed to build antigens against flu, along with a minute electric pulse, researchers have immunized experimental animals against various strains of the virus. This approach could allow for the build up of vaccine reserves that could be easily and effectively dispensed in case of an epidemic. This study was published last week in
PLoS ONE.